Up and down the ladder: The latest comings and goings

ByEd Silverman

Sept. 11, 2026

Pharmalot Columnist, Senior Writer

Ed Silverman

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morningPharmalittle newsletterand the afternoonPharmalot newsletter.

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going.

And here is our regular feature in which we highlight a different person each week. This time around, we note thatAlloy Therapeuticshired Venkat Krishnamurthy as chief scientific officer of its genetic medicines division. Previously, he held the same role at Flashpoint Therapeutics.

Advertisement

But all work and no play can make for a dull chief scientific officer.

STAT+ Exclusive Story

Already have an account?Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account?Log in

Monthly

$39

Totals $468 per year

Totals $468 per year

Starter

$30

for 3 months, then $399/year

Then $399/year

Annual

$399

Save 15%

Save 15%

11+ Users

Custom

Savings start at 25%!

Savings start at 25%!

2-10 Users

$300

Annually per user

$300 Annually per user

To read the rest of this story subscribe to STAT+.

,

,

,

1. Ed Silverman

   Pharmalot Columnist, Senior Writer

   Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morningPharmalittle newsletterand the afternoonPharmalot newsletter.

Newsletter

Understand how science, health policy, and medicine shape the world every day